GlassScriptPhysician profile
Steven J Vignale
NPI 1053369421
$6,548.10
in general payments reported to CMS, 2019-2025
38 companies · $640 in 2025
The $640 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $199 · 2021: $652 · 2022: $1,082 · 2023: $1,512 · 2024: $1,359 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $837.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $620.40 | 2022-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $602.57 | 2019-2025 | Jardiance |
| Pfizer INC. | $515.41 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $486.89 | 2019-2024 | |
| Amgen INC. | $413.23 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $411.03 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $400.31 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $338.81 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $210.47 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $182.91 | 2023-2024 | Inpefa |
| Abbott Laboratories | $171.76 | 2019-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Actelion Pharmaceuticals US, INC. | $142.17 | 2019-2024 | Opsumit |
| Boston Scientific Corporation | $124.63 | 2019-2024 | Watchman Flx, Watchman Access System |
| Cvrx, INC. | $119.29 | 2022-2024 | Barostim Neo System |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $96.89 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $91.37 | 2019-2021 | |
| Scpharmaceuticals INC. | $84.22 | 2023-2025 | |
| Vital Connect, INC | $78.11 | 2023 | Vitalpatch Rtm |
| Edwards Lifesciences Corporation | $62.93 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Heartflow, INC. | $61.55 | 2023-2024 | Ffrct |
| Kiniksa Pharmaceuticals International, Plc | $46.44 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $45.00 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $43.75 | 2023-2024 | Onpattro |
| Philips North America LLC | $42.37 | 2023-2025 | Event |
| Lundbeck LLC | $35.02 | 2019 | |
| Novo Nordisk INC | $32.31 | 2025 | Wegovy, Ozempic |
| Althera Pharmaceuticals LLC | $29.64 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.78 | 2023 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $28.48 | 2019 | |
| Biosense Webster, INC. | $26.06 | 2019 | |
| Ge Healthcare | $23.71 | 2019 | |
| Tactile Systems Technology INC | $23.70 | 2023 | Entre Plus, Flexitouch Plus |
| Chiesi USA, INC. | $22.76 | 2025 | Cleviprex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.21 | 2019-2024 | Lifevest |
| Cook Medical LLC | $18.15 | 2022 | |
| Atricure, INC. | $14.32 | 2022 | |
| Convatec INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Vignale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.